Company news

Nxera Pharma Co., Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Nxera Pharma Operational Highlights and Consolidated Results for the Third Quarter 2026

October 30, 2026

Consolidated Financial Results for the Nine Months Ended September 30, 2026 (IFRS)

October 30, 2026

Nxera Pharma Secures Exclusive Rights to Fabry Disease Phase 3 Oral Therapy Candidate Lucerastat for Japan and Selected Asia Pacific Markets

October 28, 2026

Nxera Pharma Submits Marketing Authorization Application for Vamorolone in South Korea for the Treatment of Duchenne Muscular Dystrophy

October 22, 2026

Introduction of the Executive Officer Performance Stock Option Plan and Issuance of Stock Acquisition Rights Under the Plan

October 20, 2026

Nxera Pharma Enters into Exclusive License, Supply and Commercialization Agreement with Synmosa for QUVIVIQ Across Eight Asia-Pacific Markets

October 14, 2026

Nxera Announces Successful Resolution of miniG Patent Infringement Action

October 1, 2026

Nxera Pharma to Receive $8.6 Million Milestone Payment from Centessa Pharmaceuticals Following Late-stage Development Progress

September 3, 2026

Nxera Pharma’s Partner Neurocrine Biosciences Receives IND Acceptance from the FDA for Phase 2 Study of NBI-1117567 for Alzheimer's Cognition

August 26, 2026

Nxera Pharma Operational Highlights and Consolidated Results for the Second Quarter 2026

August 7, 2026

Nxera Pharma Webinar for Financial Results Presentation - 2Q2026

July 15, 2026

OpenFold AI Research Consortium Alongside Leading Global Pharmaceutical Companies and Cloud and AI Infrastructure Technology Providers

June 10, 2026

Vamorolone Granted Key Regulatory Designations Supporting Faster Access for Duchenne Muscular Dystrophy Patients in South Korea

June 1, 2026

Nxera’s President & CEO to Participate in a ‘Fireside Chat’ at the Jefferies New York Healthcare Conference 2026

May 26, 2026

Notice of Partial Forfeiture (Decrease in the Number of Shares to be Issued, etc.) in Connection with the Issuance of New Shares Under the RSU Plan

May 18, 2026

Nxera Pharma Announces Progress of Out-Licensing of GPCR-targeted Program and Participation in Series A Financing

May 11, 2026

Nxera Files Patent Infringement Action in Relation to its miniG Platform Technology

May 8, 2026

Nxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2026

May 1, 2026

Santhera Pharmaceuticals Full Year Results for the Year Ended 31 December 2025

April 28, 2026

Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases

April 20, 2026

Notice of Issuance of New Shares in Connection with the Introduction of the Employee Stock Ownership Plan, Matters Relating to Stock Units and Determination of Payment Amount and Other Matters of Issuance of New Shares Under Prior RSU Award

April 15, 2026

Nxera Pharma’s QUVIVIQ® (daridorexant) 25mg and 50mg Receives Approval in Taiwan for the Treatment of Insomnia

April 14, 2026

Nxera Pharma’s Partner Neurocrine Biosciences Doses First Patient in Phase 2 Trial of NBI-1117570 for Adults with Schizophrenia

April 12, 2026

Nxera Pharma Achieves Second Development Milestone in Collaboration with Eli Lilly Targeting Metabolic Diseases

April 8, 2026

Nxera Pharma’s Partner Centessa Pharmaceuticals to be Acquired by Lilly

March 31, 2026

Notice Concerning New Management Structure

March 25, 2026

Full Year 2025 Trading Update

March 12, 2026

Nxera Pharma to Receive US$3 Million Milestone Payment from Centessa Pharmaceuticals

March 5, 2026

Nxera Pharma Submits Marketing Authorization Application for Daridorexant in South Korea

March 4, 2026

Nxera Pharma Proposes Changes to its Board of Directors

February 13, 2026

Nxera Pharma Operational Highlights and Consolidated Results for the Fourth Quarter and Full Year 2025

February 13, 2026

Nxera Pharma to Receive $1.8 Million Milestone Payment from Centessa Pharmaceuticals

February 12, 2026

Nxera Pharma Licenses GPCR-targeted Program to Newly Founded Spin-out Company

February 12, 2026

Nxera Pharma Webinar Presentation for FY2025 Financial Results

January 26, 2026

Nxera Pharma Establishes Metabolic Advisory Council to Advance Next-Generation Therapies for Obesity and Metabolic Disorders

January 20, 2026

Nxera Pharma Reports Positive Results From Phase 3 Trial of Daridorexant in South Korea

January 19, 2026

Nxera Pharma to Receive US$3.6 Million in Milestone Payment Pursuant to Research Collaboration with Centessa

January 13, 2026

Nxera Pharma Licenses Japan and Select Asia-Pacific Rights to Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals

January 8, 2026

Nxera Pharma to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 5, 2026

Nxera Pharma to Regain Full Rights to GPR52 Agonist Program for Schizophrenia

December 18, 2025

Nxera Introduces Employee Stock Ownership Plan (J-ESOP) for Employees Residing in Japan

November 19, 2025

Nxera Pharma Shares Video Interviews with Major Shareholders on Its Official YouTube Channel

November 17, 2025

Nxera Announces Focused Restructuring to Enhance Path to Profitability

November 17, 2025

Nxera Pharma to Host R&D Day 2025

November 4, 2025

Nxera’s President & CEO to Participate in a ‘Fireside Chat’ at the Jefferies London Healthcare Conference 2025

October 31, 2025

Nxera Pharma Receives a Manufacturing Approval Partial Amendment Regarding the Addition of a Manufacturing Site in Asia for QUVIVIQ® 25 and 50 mg

October 31, 2025

Nxera Pharma Operational Highlights and Consolidated Results for the Third Quarter and First Nine Months of 2025

October 31, 2025

Nxera’s Partner Cancer Research UK Presents Data from Successfully Completed Phase 1 Clinical Trial of Cancer Immunotherapy Drug HTL0039732 at ESMO

October 21, 2025

Nxera Pharma and Cancer Research UK Announce First Patient Dosed in Phase 2a Trial of Investigational Cancer Immunotherapy HTL0039732

September 16, 2025

Nxera Pharma Operational Highlights and Consolidated Results for the Second Quarter and First Half 2025

August 8, 2025

Older news releases →

Calls

The 5 newest of 9 calls. Every call is listed under its year.

Decks

The 5 newest of 79 decks. Every deck is listed under its year.